Topical Antimicrobial Lipid Composition Patent

The European Patent Office published patent application EP3723711A1 for Unilever covering topical antimicrobial lipid compositions. The application, filed by Unilever Global IP Limited and Unilever IP Holdings B.V., includes claims related to hair care and skin care formulations with antimicrobial properties. The patent claims priority from June 21, 2019.

SHP2 Allosteric Inhibitor Patent for Cancer Treatment

The European Patent Office granted patent EP3681879A1 to Krouzon Pharmaceuticals, Inc. covering octahydrocyclopenta[c]pyrrole compounds as allosteric inhibitors of SHP2 for cancer treatment. The patent application includes 36 designated European contracting states and covers specific chemical entities classified under A61P 35/00 (antineoplastic activity) and A61K therapeutic preparations.

Takeda patents balipodect for treating autism spectrum disorders

The European Patent Office published patent EP3856185A1 granting Takeda Pharmaceutical Company Limited exclusive rights to balipodect for treating or preventing autism spectrum disorders. The patent covers pharmaceutical compositions using the compound (classified under A61K 31/501) and was published on March 25, 2026. The designation extends to all EU member states and extension states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR.

Tri-substituted Heteroaryl Derivatives as SH2 Phosphatase Inhibitors

The European Patent Office published patent application EP3853233A1 for tri-substituted heteroaryl derivatives designed as Src Homology-2 (SH2) phosphatase inhibitors, filed by Nikang Therapeutics, Inc. The compounds are classified under IPC A61P 35/00 indicating anti-neoplastic/anti-tumor therapeutic applications. The patent is designated for all EU member states plus associated countries.

Tapentadol aqueous oral formulation patent by Grünenthal

The European Patent Office published patent application EP3597182A1 by Grünenthal GmbH on March 25, 2026, covering an aqueous pharmaceutical formulation of tapentadol for oral administration. This A1 publication makes the application details publicly available and initiates the nine-month opposition period. The patent is classified under IPC therapeutic categories A61P 25/00 and A61P 25/04, indicating analgesic applications.

Takeda patents soticlestat for epileptic encephalopathy

The European Patent Office granted Takeda Pharmaceutical Company Limited Patent EP3675852A1 covering soticlestat for treating epileptic encephalopathy. The patent was published March 25, 2026, with inventors Nishi Toshiya and Kondo Shinichi listed. The patent covers pharmaceutical compositions comprising soticlestat (A61K 31/444) for therapeutic use in seizure disorders (A61P 25/08).

Additional Phytase Variants and Methods

The European Patent Office published patent EP3737751A1 for Fornia BioSolutions' additional phytase variants and methods. The patent covers engineered phytase enzymes for industrial applications, primarily animal feed additives. The publication lists 11 inventors and was filed under IPC classifications C12N 9/16, A23K 20/189, and A23L 29/00.

DEVICE FOR FILTERING

The European Patent Office published patent application EP3870701A1 by Analytik Jena GmbH+Co. KG for a filtering device. The application was published March 25, 2026, with inventors Möller, Knippschild, and Paulenz. The patent covers biotech and sample preparation technologies classified under C12N 15/10 and G01N 1/40.

Synthetic DNA Vectors and Methods of Use

The European Patent Office published patent application EP3765023A1 for Aldevron LLC covering synthetic DNA vectors and their methods of use. The patent relates to genetic engineering applications with IPC classifications in pharmaceutical compositions (A61K) and molecular biology methods (C12N). The application designates all European member states as covered jurisdictions.

Low Sulfation Glycomolecules Patent - Conagen Inc.

The European Patent Office published patent application EP3762485A1 for Conagen Inc. covering engineered organisms and methods for producing glycomolecules with low sulfation. The patent, filed by inventors Caiazza and Urano, designates all relevant European member states including DE, FR, GB, IT, NL, and others. This is a routine patent publication in the EPO Biotechnology Bulletin with no new compliance obligations.